Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - ObsEva (Details)

v3.23.3
Licensing and Other Arrangements - ObsEva (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 21, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Asset acquisition            
Changes in estimated fair value of contingent consideration       $ 75    
Estimated useful life of intangible asset 17 years          
Amortization expense   $ 224   673    
Revenue recognized   225 $ 25 1,350 $ 3,300  
License Agreement | ObsEva            
Asset acquisition            
Contract assets   0   0   $ 0
Contract liabilities   0   0   0
Revenue recognized   0   0    
License Agreement | ObsEva, Organon            
Asset acquisition            
Maximum eligible milestone payments receivable upon achievement of milestones $ 475,000          
Maximum earn-out payments 97,500          
License Agreement | ObsEva, Organon | Development and regulatory milestones            
Asset acquisition            
Maximum earn-out payments 46,500          
License Agreement | ObsEva, Organon | Sales-based milestones            
Asset acquisition            
Maximum earn-out payments 51,000          
ObsEva IP            
Asset acquisition            
Payment for IP acquired under the ObsEva IP Acquisition Agreement 15,000          
Cost to acquire assets 15,200          
Transaction costs $ 200          
Estimated useful life of intangible asset 17 years          
Impairment of intangible asset       0   $ 0
Amortization expense   $ 200   $ 700